Navigation Links
Novel Small Molecule Therapy Shows Benefit for Anemic Patients Via Hydration of Red Blood Cells
Date:2/5/2008

hemolysis. There were no differences among the treatment groups in the overall frequency of painful crises, though crises experiences were infrequent in this study.

Senicapoc was safe and well tolerated in the study. Ten patients, five of whom were in the placebo group, discontinued the study early. Three patients dropped out due to adverse events: one in the low-dose group for weakness and shortness of breath, and two in the high-dose group for pain crises and acute chest syndrome. The most common serious adverse effect (SAE) was pain crisis, followed by pneumonia and acute chest syndrome, with a similar incidence across the active and placebo arms. None of the SAEs were thought attributable to senicapoc.

"The results we saw in this study provide further evidence that blocking the Gardos channel reduces dehydration of the sickle erythrocytes and thus supports the hypothesis that this type of approach may lead to an amelioration of the anemic state in patients with sickle cell anemia," said Dr. Ataga. "As noted in the paper, a Phase III study of senicapoc in SCD patients was recently terminated due to the low probability of achieving a reduction in crisis rate, the primary endpoint of that study. Clearly, further work is necessary to understand how the reduction in RBC dehydration and hemolysis demonstrated from the results of this Phase II study impacts the complex pathophysiology of sickle cell disease."

The American Society of Hematology (http://www.hematology.org) is the world's largest professional society concerned with the causes and treatment of blood disorders. Its mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology.


'/>"/>
SOURCE American Society of Hematology
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
2. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
3. Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF
4. Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma
5. Novel Mechanism for Long-Term Learning Identified by Carnegie Mellon Researchers
6. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
7. SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
8. PTC Therapeutics Presents Encouraging Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 30th Annual San Antonio Breast Cancer Symposium
9. Chroma Announces Positive Phase I Efficacy Data for Novel Cancer Therapy CHR-2797
10. Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
11. Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... REDWOOD CITY, Calif., Dec. 18, 2014 ... on the development of medical diagnostics based on ... of gas flow, today announced financial results for ... 30, 2014. "Following the completion of ... well positioned to maximize the recently initiated CoSense® ...
(Date:12/19/2014)... 2014   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative ... from its pivotal field study of AT-001 (Grapiprant), ... dogs with osteoarthritis.  In the study, dogs receiving ... were statistically significant compared to placebo (p<0.05) at ...
(Date:12/17/2014)... Alemania, December 17, 2014 Los ... con un alto nivel de gasto en investigación y ... 2013/14 (finalizado el 30 de septiembre de 2014) ZEISS ... 4.287 millones de euros (año anterior: 4.190 millones de ... desfavorables. Las ganancias (EBIT) crecieron un 14 por ciento, ...
Breaking Medicine Technology:Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS confirma su posición en un entorno difícil 2
... of, a Drug Target Function. A Study Performed by Sidec and ... Two Major Conformations ... Have Been Identified, STOCKHOLM, ... direct structural evidence of the molecular mechanism,of the Synaptic Vesicle protein ...
... CardioVascular,BioTherapeutics, Inc. (OTC Bulletin Board: CVBT) today announces ... for its Phase II clinical,trial for the treatment of ... announcing additional sites as they open for,enrollment. For current ... heart trial, please visit http://www.cvbt.com ., In ...
Cached Medicine Technology:The First Direct Structural Evidence of SV2A has Been Revealed Thanks to Protein Tomography(TM), and Published in BBRC 2CVBT Announces First Site to Begin Patient Enrollment for Its Phase II Heart Trial 2
(Date:12/20/2014)... Office Urgent Care of Paramus, New Jersey has served the ... treated over 40,000 patients while carrying out their mission of ... Paramus area. , For 2015, the practice is proud ... board certified physicians: Christine Milosis MD, Sandra Ugras Rey DO, ... work tirelessly to carry out The Doctor’s Office Urgent ...
(Date:12/20/2014)... Atore, Inc, (San Francisco, CA CEO: Masashi ... focused portal on December 17th, 2014. , One ... US and Japan. , MERRY BIRTHDAY SITE : ... , MERRY BIRTHDAY MESSAGE is part of 5 future ... Features, Choose from thousands of stock photos to decorate ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 Developers of ... release of a new plugin for Final Cut Pro ... , “TranSlice Volume 5 allows users to create hand ... it.” Said Christina Austin, CEO of Pixel Film Studios. ... of professionalism while maintaining an easy to use interface.” ...
(Date:12/20/2014)... 2014 Parker & Sons, Inc. a ... of experience in contractor services announces reaching a milestone ... the homeowners of Arizona. Parker and Sons is comprised ... technicians that make customer service the number one priority. ... and started with one service vehicle and has since ...
(Date:12/19/2014)... It’s very easy to become overwhelmed with ... put to the wayside until Christmas and the New Year ... “itch” and that burning desire to just escape it all ... journey to Telluride with a no-fuss, affordable package. Montrose Days ... the resort, and ensure that all accommodations are met. Plus, ...
Breaking Medicine News(10 mins):Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:Atore, Inc. Releasing the First Birthday Portal 2Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 2Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 3Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2
... The American Society,for Therapeutic Radiology and Oncology is pleased ... been selected as the 2007 Survivor,Circle Award winner. Ms. ... cash prize on Sunday, October 28, 2007, at 8:00 ... Annual Meeting, which will,take place October 28 through November ...
... 16 The Center for the Internet & Digital,Medicine ... Eleanor,Herriman, MD, MBA, will chair a panel on Business ... at the 3rd Annual World,Healthcare Innovation and Technology Congress ... from 2 to 3 pm. CIDM develops and ...
... Moved Atlanta Office to Larger Space and Constructed New ... Outcomes Strategy ... ECLP ), The Outcomes Company(R), today announced,that it will move ... will take place over the next few months with,completion expected by ...
... for next-generation sensors, researchers have crafted a layered material ... manner nature never intended. , Refraction always bends light ... of a "bent" drinking straw when observed through the ... alternating layers of semiconductors (indium-gallium-arsenic and aluminum-indium-arsenic) acts as ...
... covered by current pediatric vaccine, making it tough to ... -- An emerging "superbug" that causes ear infections in ... be treated with an adult medication, researchers report. , ... strain of Streptococcus pneumoniae that caused ear ...
... Highlands Acquisition Corp.,(Amex: HIA.U), (the "Company") announced today that, ... units may elect to separately trade,the common stock and ... warrants will be quoted on the American Stock Exchange ... will continue to,trade on the American Stock Exchange under ...
Cached Medicine News:Health News:L.A. Breast Cancer Activist Honored With Survivor Circle Award 2Health News:L.A. Breast Cancer Activist Honored With Survivor Circle Award 3Health News:CIDM Collaborates With World Congress to Advance Dialog on Online Provider Networks at WHIT 3.0 2Health News:Eclipsys Announces Relocation of Corporate Headquarters to Atlanta, GA 2Health News:Ear Infections Linked to Drug-Resistant 'Superbug' 2Health News:Ear Infections Linked to Drug-Resistant 'Superbug' 3Health News:Ear Infections Linked to Drug-Resistant 'Superbug' 4Health News:Highlands Acquisition Corp. Announces Separate Trading of Common Stock and Warrants 2
Reusable, stainless steel trephine with handle....
Reusable, stainless steel trephine with handle....
Reusable, stainless steel trephine with handle....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Medicine Products: